# US 2026/0151345 A1 · Fast-dissolving dosage forms and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0151345 A1
- Document ID: US20260151345A1
- Status: Published application
- Kind: A1
- Application number: 19/126,330
- Filed: 2023-11-03
- Published: 2026-06-04
- Earliest claimed: 2022-11-03
- Assignees: Astrocyte Pharmaceuticals, Inc.
- Applicants: Astrocyte Pharmaceuticals, Inc.
- Inventors: Russell Birch Poe; Leon Paul Grother
- Web page: https://patentgrep.com/patent/US20260151345A1

## CPC

- A61K 9/2063: {Proteins, e.g. gelatin}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/1658: {Proteins, e.g. albumin, gelatin}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2095: {Tabletting processes}
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to pharmaceutical compositions for oral administration of A3R agonist compounds. The compositions are designed to disintegrate or disperse rapidly to deliver an effective dose of the compound for treating, ameliorating, or promoting recovery from certain conditions of the brain, central nervous system (CNS), or cardiovascular system such as a brain injury, a neurodegenerative condition, or cardiac ischemia.

## Claims

### Claim 1

A pharmaceutical composition, comprising:
(a) compound A:
(b) A matrix former;
(c) A structure former; and, optionally,
(d) A flavoring agent and/or sweetening agent;
wherein the composition disintegrates in water at 20° C. in about 30 seconds or less.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the structure former comprises mannitol, PEG 400, hydrolyzed dextrose, dextran, dextrin, maltodextrin, an alginate, hydroxyethylcellulose, carboxymethylcellulose, microcrystalline cellulose, com-syrup solids, pectin, carrageenan, agar, chitosan, locust bean gum, xanthan gum, guar gum, acacia gum, tragacanth, konjac flour, rice flour, wheat gluten, sodium starch glycolate, soy fiber protein, potato protein, papain, glycine, sorbitol, erythritol, lactose, D-glucitol, trehalose, xylitol, or maltose; or a combination of two or more thereof.

### Claim 3 (depends on 1, 2)

The composition of claim 1 or 2, wherein the structure former comprises mannitol.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the mannitol is present as about 2.0% to about 60.0% w/w of the composition.

### Claim 5 (depends on 3)

The composition of claim 3, wherein the mannitol is present as about 10.0% to 24.0% w/w of the composition.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the mannitol is present as about 16.0% w/w of the composition.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of any one of claims 1-6, wherein the matrix former comprises a water-soluble or water-dispersible pharmaceutically acceptable carrier.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The composition of any one of claims 1-7, wherein the matrix former comprises gelatin, pullulan, starch, or combinations thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The composition of any one of claims 1-8, wherein the matrix former comprises fish gelatin, bovine gelatin, porcine gelatin, or combinations thereof.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the gelatin comprises Gel NonOx (Gelita), HMW (High Molecular Weight) bovine or HMW fish gelatin.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the gelatin comprises HMW fish gelatin.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11, wherein the matrix former is present in an about 5:1 w/w to about 1:5 w/w ratio with the structure former.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11, wherein the matrix former is present in an about 1:1.25 w/w ratio with the structure former.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11, wherein the matrix former is present as about 2.0% to about 60.0% w/w of the composition.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11, wherein the matrix former is present as about 10.0% to about 40.0% w/w of the composition.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The composition of any one of claims 1-11, wherein the matrix former is present as about 14.0% to about 24.0% w/w of the composition.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The composition of any one of claims 1-16, wherein compound A is present as about 4% to about 90% w/w of the composition.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The composition of any one of claims 1-16, wherein compound A is about 20% to about 80% w/w of the composition.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The composition of any one of claims 1-16, wherein compound A is about 52% w/w of the composition.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The composition of any one of claims 1-19, wherein compound A is in the form of a hemi-hydrate.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The composition of any one of claims 1-20, wherein compound A comprises Form A having peaks in its XRPD at 8.0±0.2, 13.1±0.2, 16.2±0.2, 16.7±0.2, and 17.9±0.2 degree 2-theta.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The composition of any one of claims 1-21, wherein compound A is provided as a solid having D90 of less than 30 μm prior to inclusion in the composition.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The composition of any one of claims 1-22, wherein the composition contains no more than 0.8% by HPLC, as compared to the AUC (area under the curve) of compound A, of the following compound:

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The composition of any one of claims 1-23, wherein the flavoring agent is present and is selected from coconut, orange, cherry, fruit punch, lemon, lime, grapefruit, raspberry, tutti-frutti, black cherry, strawberry, mint, peppermint, and combinations thereof; and the sweetening agent is present and is selected from sucrose, glucose, sucralose, fructose, lactose, aspartame, invert sugar, corn syrup, stevia extract powder, stevioside, steviol, saccharin, saccharin salts, potassium acetosulfam, sorbitol, xylitol, mannitol, erythritol, lactitol, alitame, miraculin, monellin, and thaumatin or a combination of the same.

### Claim 25 (depends on 24)

The composition of claim 24, comprising about 0.10% w/w sucralose and about 0.2% w/w peppermint.

### Claim 26 (depends on 1)

The composition of claim 1, comprising:
(a) compound A:
as about 4.0% to about 90.0% w/w of the composition;
(b) A matrix former comprising about 10.0% to about 40.0% w/w gelatin;
(c) A structure former comprising about 10% to about 24.0% mannitol; and, optionally,
(d) A flavoring agent and/or sweetening agent;
wherein the composition disintegrates in water at 20° C. in about 30 seconds or less.

### Claim 27 (depends on 26)

The composition of claim 26, wherein compound A is present as about 40.0% to about 80% w/w of the composition; the matrix former comprises about 16.0% to about 24.0% w/w gelatin; and the structure former comprises about 12.0% to about 20.0% w/w mannitol.

### Claim 28 (depends on 26)

The composition of claim 26, wherein compound A is present as about 52.0% w/w of the composition; the matrix former comprises about 20.0% w/w HMW fish gelatin; and the structure former comprises about 16.0% w/w mannitol.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The composition of any one of claims 1-28, wherein the composition disintegrates in water at 20° C. in about 12 seconds or less.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The composition of any one of claims 1-28, wherein the composition disintegrates in water at 20° C. in about 7 seconds or less.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The composition of any one of claims 1-28, wherein the composition disintegrates in water at 20° C. in about 0.5 to about 5 seconds.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

A unit dosage form comprising the composition of any one of claims 1-31, wherein the unit dosage form contains about 15 mg to about 1800 mg of compound A.

### Claim 33 (depends on 27)

The unit dosage form of claim 27, containing about 25 mg to about 1200 mg of compound A.

### Claim 34 (depends on 27)

The unit dosage form of claim 27, containing about 50 mg, about 150 mg, about 300 mg, or about 900 mg of compound A.

### Claim 35 (depends on 32, 33, 34)

The unit dosage form of any one of claims 32-34, wherein the unit dosage form is an oral disintegrating tablet (ODT), granules, minitablet, mucoadhesive tablet, sublingual tablet, chewable tablet, or effervescent tablet.

### Claim 36 (depends on 32, 33, 34)

The unit dosage form of any one of claims 32-34, wherein the unit dosage form is an oral disintegrating tablet (ODT).

### Claim 37 (depends on 32, 33, 34, 35, 36)

The unit dosage for of any one of claims 32-36, wherein the unit dosage forms comprises compound A in the form of a hemi-hydrate.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

A method of preparing a pharmaceutical composition of any one of claims 1-28, comprising:
(i) mixing water, a matrix former, and a structure former to form a pre-mix;
(ii) optionally, modifying the pH of the pre-mix to a desired pH value;
(iii) optionally, heating the pre-mix to a temperature of about 20-70° C.;
(iv) optionally, adding a flavoring agent:
(v) adding compound A:
(vi) agitating the mix until compound A is dissolved, if compound A is not fully dissolved:
(vii) optionally, heating or cooling the mix of step (vi) to a temperature between about 10° C. and about 40° C.; and
(viii) removing the water and any volatile components.

### Claim 39 (depends on 36)

A method of preparing an oral disintegrating tablet (ODT) of claim 36, comprising:
(i) dosing a pharmaceutical composition into a preformed mold, wherein the pharmaceutical composition comprises a matrix former, a structure former, compound A:
and, optionally, a flavoring agent and/or sweetening agent;
(ii) freezing the pharmaceutical composition; and
(iii) freeze-drying the pharmaceutical composition to form the ODT.

### Claim 40 (depends on 38)

The method of claim 38, wherein compound A is provided in step (v) in the form of a hemi-hydrate.

### Claim 41 (depends on 40)

The method of claim 40, wherein compound A comprises Form A having peaks in its XRPD at 8.0±0.2, 13.1±0.2, 16.2±0.2, 16.7±0.2, and 17.9±0.2 degree 2-theta.

### Claim 42 (depends on 38)

The method of claim 38, wherein compound A is provided in anhydrous form.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of treating an injury, disease, or condition selected from traumatic brain injury (TBI), concussion, stroke, polytrauma, cardiac arrest, near drowning, altitude sickness, brain injuries from directed energy or Havanna Syndrome, partial or total spinal cord transection, malnutrition, toxic neuropathies, meningoencephalopathies, neurodegeneration caused by a genetic disorder, age-related neurodegeneration, vascular disease, Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD), Multiple Sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), cardiovascular disease, autoimmune diseases, allergic diseases, transplant rejection, graft-versus-host disease, intraocular hypertension, glaucoma, odor sensitivity, an olfactory disorder, type 2 diabetes, pain control, respiratory diseases, deficits in CNS function, deficits in learning, deficits in cognition, otic disorders, Meniere's disease, endolymphatic hydrops, progressive hearing loss, noise-induced hearing loss, dizziness, vertigo, tinnitus, collateral brain damage associated with radiation cancer therapy, migraine treatment, sleep disorders in the elderly, epilepsy, schizophrenia, symptoms experienced by recovering alcoholics, damage to neurons or nerves of the peripheral nervous system during surgery, gastrointestinal conditions, pain mediated by the CNS, migraine, collateral brain damage associated with radiation cancer therapy, depression, mood or behavioral changes, dementia, erratic behavior, suicidality, tremors, Huntington's chorea, loss of coordination of movement, deafness, impaired speech, dry eyes, hypomimia, attention deficit, memory loss, cognitive difficulties, vertigo, dysarthria, dysphagia, ocular abnormalities or disorientation, and addiction;
comprising administering to a patient in need thereof an effective amount of a composition of any one of claims 1-26.

### Claim 44 (depends on 43)

The method of claim 43, wherein the injury, disease, or condition is selected from acute pain, chronic pain, nociceptive pain, neuropathic pain, inflammatory pain, and acute pain.

### Claim 45 (depends on 43)

The method of claim 43, wherein the pain is selected from musculoskeletal pain, fibromyalgia, myofascial pain, pain during menstruation, pain during osteoarthritis, pain during rheumatoid arthritis, pain during gastrointestinal inflammation, pain during inflammation of the heart muscle, pain during multiple sclerosis, pain during neuritis, pain during AIDS, pain during chemotherapy, tumor pain, headache, chronic pain syndrome (CPS), central pain, trigeminal neuralgia, shingles, stamp pain, phantom limb pain, temporomandibular joint disorder, nerve injury, migraine, post-herpetic neuralgia, neuropathic pain encountered as a consequence of injuries, amputation infections, metabolic disorders or degenerative diseases of the nervous system, neuropathic pain associated with diabetes, pseudesthesia, hypothyroidism, uremia, vitamin deficiencies or alcoholism, acute pain after injuries, postoperative pain, pain during acute gout, and pain from an operation.

### Claim 46 (depends on 43)

The method of claim 43, wherein the injury, disease, or condition is selected from traumatic brain injury (TBI), stroke, a neurodegenerative condition, and a heart and cardiovascular disease.

### Claim 47 (depends on 46)

The method of claim 46, wherein the injury, disease, or condition is TBI selected from concussion, blast injury, combat-related injury, a mild, moderate or severe blow to the head, whiplash, sports-related injury, or a head injury sustained from a fall or other accident.

### Claim 48 (depends on 46)

The method of claim 46, wherein the injury, disease, or condition is a stroke selected from ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, and transient ischemic attacks (TIA).

### Claim 49 (depends on 43, 44, 45, 46, 47, 48)

The method of any one of claims 43-48, wherein neuroprotection or neurorestoration is increased in the patient as compared with an untreated patient.

### Claim 50 (depends on 43)

The method of claim 43, wherein the injury, disease, or condition is a neurodegenerative disease selected from Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD), Multiple Sclerosis (MS), amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), and a neurodegenerative condition caused by a virus, alcoholism, tumor, toxin, or repetitive brain injuries.

### Claim 51 (depends on 43)

The method of claim 43, wherein the injury, disease, or condition is heart or cardiovascular disease selected from cardiac ischemia, myocardial infarction, a cardiomyopathy, coronary artery disease, arrhythmia, myocarditis, pericarditis, angina, hypertensive heart disease, endocarditis, rheumatic heart disease, congenital heart disease, and atherosclerosis.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of increasing neuroprotection or neurorestoration in a patient in need thereof who has suffered a TBI or stroke, comprising administering to the patient an effective amount of the composition of any one of claims 1-26.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of treating an injury, disease, disorder, or condition selected from:
(i) brain damage caused by radiation or collateral brain damage associated with radiation cancer therapy or migraine treatment;
(ii) migraine headache;
(iii) a condition associated with a brain injury or a neurodegenerative condition; and
(iv) an autoimmune disease or condition, glaucoma, an otic disorder, progressive hearing loss, tinnitus, epilepsy, pain control, pain mediated by the CNS, neuropathic pain, inflammatory pain, or acute pain:
comprising administering to a patient in need thereof an effective amount of the composition of any one of claims 1-26.

### Claim 54 (depends on 53)

The method of claim 53, wherein the composition increases neuroprotection or neurorestoration in the patient as compared with an untreated patient.

### Claim 55 (depends on 53)

The method of claim 53, wherein the condition associated with a brain injury or a neurodegenerative condition is selected from epilepsy, migraine, collateral brain damage associated with radiation cancer therapy, depression, mood or behavioral changes, dementia, erratic behavior, suicidality, tremors, Huntington's chorea, loss of coordination of movement, deafness, impaired speech, dry eyes, hypomimia, attention deficit, memory loss, cognitive difficulties or deficit in cognition, deficit in CNS function, deficit in learning, vertigo, dysarthria, dysphagia, ocular abnormalities, and disorientation.

### Claim 56 (depends on 53)

The method according to claim 53, wherein the injury, disease, or condition is migraine.

### Claim 57 (depends on 53)

The method according to claim 53, wherein the injury, disease, or condition is pain selected from central pain syndrome, peripheral neuropathy, corneal neuropathic pain, post stroke pain, and pain caused by multiple sclerosis.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of increasing cardioprotection or regeneration of damaged heart tissue in a patient in need thereof who has suffered a cardiac ischemia or myocardial infarction, comprising administering to the patient an effective amount of the composition of any one of claims 1-26.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of treating an addiction, addictive behavior, behavioral addiction, brain reward system disorder, or a compulsive disorder, comprising administering to a patient in need thereof an effective amount of the composition of any one of claims 1-26.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 43-59, wherein the composition of any one of claims 1-26 is administered once an hour, every hour, for 1 to 8 hours.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 43-59, wherein the composition of any one of claims 1-26 is administered once an hour or once every two hours.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 43-59, wherein the composition of any one of claims 1-26 is administered up to three times over five hours.
